Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) (NSEIFSC:DRREDDY) announced on Wednesday that it has launched US Food and Drug Administration (FDA) approved Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade (bortezomib) Injection, in the US market.

Bortezomib for injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and mantle cell lymphoma.

Dr. Reddy's Bortezomib for Injection is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.

According to IQVIA Health, the Velcade brand and generic had US sales of approximately USD1.2bn MAT for the 12 months ending in May 2022.

Dr. Reddy's Laboratories offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's major markets include the US, India, Russia & CIS countries and Europe.